Premature cardiovascular disease in young women with heterozygous familial hypercholesterolemia

References

• Goldstein JL, Hobbs HH, Brown HS. The Metabolic Basis of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D (Eds.). McGraw-Hill, NY, USA. 2863–2913 (2001).
   Google Scholar
• Vohl MC, Moorjani S, Roy M et al. Geographic distribution of French–Canadian low-density lipoprotein receptor gene mutations in the province of Quebec. Clin. Genet.52, 1–6 (1997).
   Google Scholar
• de Jongh S, Lilien MR, Bakker HD et al. Family history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia. Atherosclerosis163, 193–197 (2002).
   PubMed Web of Science ®Google Scholar
• Wiegman A, Groot E, Hutten BA et al. Arterial intima-media thickness i n children heterozygous for familial hypercholesterolemia. Lancet363, 369–370 (2004).
   Google Scholar
• Jansen AC, van WS, Defesche JC, Kastelein JJ. Phenotypic variability in familial hypercholesterolaemia: an update. Curr. Opin. Lipidol.13, 165–171 (2002).
   PubMed Web of Science ®Google Scholar
• Koeijvoets KC, Rodenburg J, Hutten BA et al. Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trial. Circulation112, 3168–3173 (2005).
   PubMedGoogle Scholar
• Umans-Eckenhausen MA, Sijbrands EJ, Kastelein JJ, Defesche JC. Low-density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population. Circulation106, 3031–3036 (2002).
   PubMed Web of Science ®Google Scholar
• Gaudet D, Vohl MC, Couture P et al. Contribution of receptor negative versus receptor defective mutations in the LDL-receptor gene to angiographically assessed coronary artery disease among young (25–49 years) versus middle-aged (50–64 years) men. Atherosclerosis143, 153–161 (1999).
   Google Scholar
• Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet2, 1380–1382 (1969).
   PubMed Web of Science ®Google Scholar
• Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis142, 105–112 (1999).
   PubMed Web of Science ®Google Scholar
• Beaumont V, Jacotot B, Beaumont JL. Ischaemic disease in men and women with familial hypercholesterolaemia and xanthomatosis. A comparative study of genetic and environmental factors in 274 heterozygous cases. Atherosclerosis24, 441–450 (1976).
   PubMed Web of Science ®Google Scholar
• Gagne C, Moorjani S, Brun D, Toussaint M, Lupien PJ. Heterozygous familial hypercholesterolemia. Relationship between plasma lipids, lipoproteins, clinical manifestations and ischaemic heart disease in men and women. Atherosclerosis34, 13–24 (1979).
   PubMed Web of Science ®Google Scholar
• Hill JS, Hayden MR, Frohlich J, Pritchard PH. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler. Thromb.11, 290–297 (1991).
   PubMed Web of Science ®Google Scholar
• Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Br. Med. J.303, 893–896 (1991).
   PubMed Web of Science ®Google Scholar
• Jansen AC, van Aalst-Cohen ES, Tanck MW et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J. Intern. Med.256, 482–490 (2004).
   PubMed Web of Science ®Google Scholar
• Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science308, 1583–1587 (2005).
   PubMed Web of Science ®Google Scholar
• Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N. Engl. J. Med.340, 1801–1811 (1999).
   PubMed Web of Science ®Google Scholar
• Farhat MY, Lavigne MC, Ramwell PW. The vascular protective effects of estrogen. FASEB J.10, 615–624 (1996).
   PubMed Web of Science ®Google Scholar
• Arnal JF, Bayard F. Vasculoprotective effects of oestrogens. Clin. Exp. Pharmacol. Physiol.28, 1032–1034 (2001).
   Google Scholar
• Skafar DF, Xu R, Morales J, Ram J, Sowers JR. Clinical review 91: female sex hormones and cardiovascular disease in women. J. Clin. Endocrinol. Metab.82, 3913–3918 (1997).
   PubMed Web of Science ®Google Scholar
• Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis98, 83–90 (1993).
   PubMed Web of Science ®Google Scholar
• Jensen J, Nilas L, Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas12, 321–331 (1990).
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA288, 321–333 (2002).
   PubMed Web of Science ®Google Scholar
• Magliano DJ, Rogers SL, Abramson MJ, Tonkin AM. Hormone therapy and cardiovascular disease: a systematic review and meta-analysis. BJOG113, 5–14 (2006).
   PubMed Web of Science ®Google Scholar
• Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA288, 872–881 (2002).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation100, 1481–1492 (1999).
   PubMed Web of Science ®Google Scholar
• Yagi K, Hifumi S, Nohara A et al. Difference in the risk factors for coronary, renal and other peripheral arteriosclerosis in heterozygous familial hypercholesterolemia. Circ. J.68, 623–627 (2004).
   PubMed Web of Science ®Google Scholar
• Miettinen TA, Gylling H. Mortality and cholesterol metabolism in familial hypercholesterolemia. Long-term follow-up of 96 patients. Arteriosclerosis8, 163–167 (1988).
   PubMedGoogle Scholar
• Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation49, 476–488 (1974).
   PubMed Web of Science ®Google Scholar
• Ashen MD, Blumenthal RS. Clinical practice. Low HDL cholesterol levels. N. Engl. J. Med.353, 1252–1260 (2005).
   PubMed Web of Science ®Google Scholar
• Ellison RC, Zhang Y, Qureshi MM et al. Lifestyle determinants of high-density lipoprotein cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study. Am. Heart J.147, 529–535 (2004).
   PubMed Web of Science ®Google Scholar
• de Sauvage Nolting PR, Defesche JC, Buirma RJ et al. Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia. J. Intern. Med.253, 161–168 (2003).
   Google Scholar
• Hopkins PN, Stephenson S, Wu LL et al. Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia. Am. J. Cardiol.87, 547–553 (2001).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation110, 227–239 (2004).
   PubMed Web of Science ®Google Scholar
• Hopkins PN. Familial hypercholesterolemia–improving treatment and meeting guidelines. Int. J. Cardiol.89, 13–23 (2003).
   Web of Science ®Google Scholar
• Connor WE, Connor SL. Importance of diet in the treatment of familial hypercholesterolemia. Am. J. Cardiol.72, 42D–53D (1993).
   PubMed Web of Science ®Google Scholar
• Law M. Plant sterol and stanol margarines and health. Br. Med. J.320, 861–864 (2000).
   PubMed Web of Science ®Google Scholar
• Katan MB, Grundy SM, Jones P et al. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin. Proc.78, 965–978 (2003).
   PubMed Web of Science ®Google Scholar
• Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA285, 2486–2497 (2001).
   PubMed Web of Science ®Google Scholar
• Grundy SM. Stanol esters as a component of maximal dietary therapy in the National Cholesterol Education Program Adult Treatment Panel III report. Am. J. Cardiol.96, 47D–50D (2005).
   PubMed Web of Science ®Google Scholar
• Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis173, 55–68 (2004).
   Google Scholar
• Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med.333, 1301–1307 (1995).
   PubMed Web of Science ®Google Scholar
• Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis168, 1–14 (2003).
   PubMed Web of Science ®Google Scholar
• Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis142, 105–112 (1999).
   PubMed Web of Science ®Google Scholar
• Betteridge DJ, Bhatnager D, Bing RF et al. Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine. Br. Med. J.304, 1335–1338 (1992).
   Google Scholar
• de Sauvage Nolting PR, Buirma RJ, Hutten BA, Kastelein JJ. Two-year efficacy and safety of simvastatin 80 mg in familial hypercholesterolemia (the Examination of Probands and Relatives in Statin Studies With Familial Hypercholesterolemia [ExPRESS FH]). Am. J. Cardiol.90, 181–184 (2002).
   PubMed Web of Science ®Google Scholar
• Smilde TJ, van Wissen S, Wollersheim H et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet357, 577–581 (2001).
   PubMed Web of Science ®Google Scholar
• Stein EA, Strutt K, Southworth H, Diggle PJ, Miller E. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am. J. Cardiol.92, 1287–1293 (2003).
   PubMed Web of Science ®Google Scholar
• The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA20(251), 351–364 (1984).
   Google Scholar
• Davidson MH, Dillon MA, Gordon B et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch. Intern. Med.159, 1893–1900 (1999).
   PubMed Web of Science ®Google Scholar
• Rodenburg J, Vissers MN, Daniels SR, Wiegman A, Kastelein. Lipid-lowering Medications. Pediatr. Endocrinol. Rev.2, 109–119 (2006).
   Google Scholar
• Dujovne CA, Ettinger MP, McNeer JF et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am. J. Cardiol.90, 1092–1097 (2002).
   PubMed Web of Science ®Google Scholar
• Gagne C, Bays HE, Weiss SR et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am. J. Cardiol.90, 1084–1091 (2002).
   PubMed Web of Science ®Google Scholar
• Walsh JM, Pignone M. Drug treatment of hyperlipidemia in women. JAMA291, 2243–2252 (2004).
   PubMed Web of Science ®Google Scholar
• Wiegman A, Hutten BA, de Groot E et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA292, 331–337 (2004).
   PubMed Web of Science ®Google Scholar
• Greene O, Durrington P. Clinical management of children and young adults with heterozygous familial hypercholesterolaemia in the UK. J. R. Soc. Med.97, 226–229 (2004).
   Google Scholar
• Bhargava R, Sandhu G, Armstrong M et al. Gender bias in the use of lipid-lowering therapy. Circulation112, II–817 (2006).
   Google Scholar